Mabxience Research S.l.
Clinical trials sponsored by Mabxience Research S.l., explained in plain language.
-
New biosimilar aims to match leading melanoma treatment
Disease control Recruiting nowThis study tests whether MB11, a biosimilar (a nearly identical copy) of the cancer drug nivolumab (Opdivo), works as well as the original drug in people with advanced melanoma that cannot be removed by surgery or has spread. About 632 adults who have not yet been treated for the…
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC
-
Could a cheaper keytruda copy work just as well for lung cancer?
Disease control Recruiting nowThis study compares a new, potentially more affordable drug called MB12 (a biosimilar to Keytruda) to the original Keytruda, both given with chemotherapy, as a first treatment for people with advanced stage IV non-squamous non-small cell lung cancer. About 726 adults who have not…
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC